[Blood stem cell transplantation in pediatric oncology]

Large-dose chemotherapy (LDCT) with auto- and allogenic transplantation of blood stem cells (BSC) in pediatric oncology remains so far the last hope for many patients. The number of such procedures made in Europe increases by 10% every year. At the same time many issues of the place and role of transplantation in pediatric oncology remains unclear. Based on 240 sessions of cytopheresis, the author show that BSC can be sampled from severe pretreated patients despite the drug therapy regimen. The efficacy of G-KSF and GM-KSF used to stimulate BSC secretion is similar. After LDCT with BSC autotransplantation, the relapse-free survival rates in patients with Ewing's sarcoma and acute myeloblast-cell leukemia were 55.4 and 44.4%, respectively (in the first and second remissions). Consolidation as LDCT with BSC autotransplantation without cleansing the material from malignant cells is not a sufficient therapeutical measurement in disseminated neuroblastoma. Whether partial compatible related BSC transplantation can be possible made after non-myeloablative preparation regimens is shown.